Table 4.
ALLY-2: SVR12 in Patients With Genotype 1 and 3 HCV/HIV Coinfection Treated With Daclatasvir in Combination With Sofosbuvir for 12 Weeks8
| Treatment Outcomes | Total (N = 137) |
|---|---|
|
| |
| SVR12 | |
| Genotype 1 | 97% (123/127) |
| No cirrhosisa | 98% (103/105) |
| With cirrhosis | 91% (20/22) |
| Genotype 3b | 100% (10/10) |
|
| |
| Outcomes for genotype 1 patients without SVR12 | |
| On-treatment virological failurec | 0.8% (1/127) |
| Relapsed | 1.6% (2/126) |
| Missing post-treatment data | 0.8% (1/126) |
HCV = hepatitis C virus; HIV = human immunodeficiency virus; SVR12 = sustained virological response at post-treatment week 12.
a
Includes five patients with inconclusive cirrhosis status.
b
One patient with cirrhosis.
c
One patient had detectable HCV RNA at end of treatment.
d
Relapse rates are calculated with a denominator of patients with HCV RNA not detected at the end of treatment.